Financial Performance - In 2024, the total revenue reached 367.3 billion CNY, with a year-on-year growth of 5.1% [3] - The net profit attributable to shareholders was 116.7 billion CNY, showing a growth of 0.7% after excluding financial expenses [3] - Operating cash flow net amount was 124.3 billion CNY, reflecting a year-on-year increase of 12.4% [3] - For Q1 2025, revenue was 82.4 billion CNY, a decrease of 12.1% compared to Q1 2024 [3] - The net profit for Q1 2025 was 26.3 billion CNY, down 16.8% from Q1 2024 [3] Shareholder Returns - The total dividend amount for 2024 was 76.0 billion CNY, an increase of 8.1% year-on-year [4] - The dividend payout ratio for 2024 was 65.1% [5] - The company plans to distribute 6.8 billion CNY in 2025 and aims for a total of 17.1 billion CNY in the first mid-year profit distribution [4] Business Segments - The in-vitro diagnostics segment generated 137.6 billion CNY in revenue, with a year-on-year growth of 10.8% [6] - The medical imaging segment reported 75.0 billion CNY in revenue, growing by 6.6% [6] - The life information and support segment had revenue of 135.6 billion CNY, down 11.1% year-on-year [6] - International revenue accounted for 44.7% of total revenue, with significant growth in developing countries [6] R&D and Innovation - R&D investment reached 40.1 billion CNY, constituting 10.9% of total revenue [6] - The company holds a total of 5,786 patents, with a focus on innovation in AI and smart healthcare solutions [6] AI and Smart Healthcare Initiatives - The launch of the "Qiyuan Critical Care Medical Model" in December 2024 integrates IoT, cloud computing, and AI to enhance clinical decision-making [8] - The model has been implemented in several top medical institutions, improving efficiency and accuracy in critical care [9] Market Expansion - By the end of 2024, the company had installed equipment in over 1,600 hospitals domestically, with significant growth in tier-3 hospitals [11] - Internationally, the "M-Connect" project has signed contracts with over 650 projects, with 250 new contracts in 2024 [11] - The "Ruiying Cloud ++" platform has been deployed in multiple countries, enhancing remote training and academic exchange [13]

Group 1: Financial Performance - The company's revenue and net profit declined significantly in 2024 due to deferred customer demand, delayed delivery acceptance, and the ongoing upgrade of the new product WiNEX, which has not yet converted into substantial revenue [17][11]. - In Q1 2025, the company reported a notable improvement in bidding amounts, indicating a potential recovery in market conditions [8][4]. - The company's gross profit margin has decreased primarily due to deferred customer demand and delays in the bidding process [14]. Group 2: Research and Development - The company reduced R&D expenses from CNY 333 million in 2023 to CNY 265 million in 2024, attributed to the maturation of the WiNEX product [5][9]. - In 2024, R&D investment was CNY 562 million, accounting for 20.21% of revenue, maintaining an average of over 20% in the past three years [12][7]. Group 3: Accounts Receivable and Debt Management - The company has seen a continuous increase in accounts receivable and contract assets, with government debt relief measures expected to improve collection rates [6][16]. - The company has a cautious approach to impairment loss provisions, reflecting the long payment cycles typical of public hospitals and health management departments [18]. Group 4: Market Position and Competition - The company believes it has a competitive edge in AI applications within the healthcare sector, having established an AI laboratory in 2017 and launched the WiNGPT product [15][3]. - The entry of major telecom operators into the healthcare information market is seen as a temporary challenge, with expectations of improvement in the future [10][6]. Group 5: Strategic Adjustments - The company has proactively abandoned low-quality hardware projects to focus on more profitable software and AI-related services [19][10]. - The company plans to enhance its market share and improve profitability through cost control and efficient project delivery [20][17].

Core Viewpoint - The conference aimed to promote the high-quality collection, governance, secure circulation, and innovative application of healthcare data in Fujian Province, thereby empowering the high-quality development of the medical industry in the region [1][3]. Group 1: Conference Overview - The conference, themed "Digital Intelligence Integration, Medical Innovation Future," was held in Fuzhou on April 18, focusing on the value of medical data and the integration of technology and industry [1][3]. - The event featured numerous domestic and international experts discussing cutting-edge technologies, application scenarios, and policy directions in the field of medical artificial intelligence [4]. Group 2: Expert Contributions - Notable contributions included a lecture by academician Zheng Hairong from Nanjing University, who discussed the broad application prospects of artificial intelligence in healthcare, covering areas such as medical imaging, precision diagnosis, and drug screening [4]. - Other experts shared insights on health data investment funds, data construction in Fujian, and the exploration of large medical models, showcasing their research findings and practical experiences [7]. Group 3: Supply and Demand Matching - The supply and demand matching segment attracted significant attention, featuring 49 medical AI demand projects and 23 medical AI products, along with the release of the "Fujian Province Medical Artificial Intelligence Supply and Demand Matching Manual" [7][8]. - Initial cooperation intentions were established between multiple enterprises and medical institutions during the event, laying a solid foundation for future collaborations [7]. Group 4: Strategic Partnerships - A signing ceremony took place, with representatives from Fujian Province Big Data Group and other companies committing to strategic cooperation in the field of medical AI data elements [8]. - The implementation of these signed projects is expected to enhance the innovation capacity and competitiveness of Fujian's medical AI sector, injecting strong momentum into the healthcare industry [8]. Group 5: Future Development Goals - Fujian Province aims to solidify its data foundation, integrate provincial data resources, and promote innovative applications of medical data, with plans to build a smart medical system covering the entire chain of disease prevention, diagnosis, and rehabilitation [10]. - The province will also focus on attracting and cultivating high-end talent, enhancing international collaboration, and improving the overall strength and global influence of its medical AI sector [10].